Omeprazole is frequently indicated for disorders related to hyperacidity, such as gastroesophageal reflux disease and Helicobacter pylori infections. Spain has the highest omeprazole consumption rate among Organization for Economic Co-operation and Development (OECD) nations, measured in defined daily doses per 1000 inhabitants per day (DHD), suggesting possible patterns of overutilization and improper administration. Community pharmacists play a critical role in partnering with medical professionals to mitigate safety hazards and optimize therapeutic results. Characterize the demographic and clinical profiles of omeprazole consumers to guide the development of pharmaceutical care (PC) initiatives tailored to distinct patient needs and enhance safety. An observational, cross-sectional design (CEIm Code FCF-OME-2023-01) was used to evaluate 100 omeprazole consumers at a Barcelona community pharmacy between November 2023 and May 2024. Information was gathered through structured clinical interviews utilizing a specialized Data Collection Questionnaire. Within the omeprazole cohort, 49% were male, 51% were female, and 56% were 65 years of age or older. Extended use of the medication was identified in a large majority (71%), and 30% met the criteria for polymedication (concomitant use of five or more drugs). Remarkably, 52% of individuals presented without a documented history of gastric pathology. Furthermore, episodic consumption was reported by 22% of participants following short-term, as-needed therapeutic protocols, whereas 78% followed a continuous daily administration routine. Within the latter group, inadequate treatment adherence was observed in 29.5% of cases. An evaluation of medication-related problems (MRPs) among the 78 individuals on long-term daily omeprazole therapy demonstrated that the most frequent issues included “unnecessary medication”, “lack of adherence”, “wrong administration”, “drug interactions”, and “lack of knowledge regarding medication use”. According to the STOPP criteria, 45% of the study population qualified for discontinuation or dose reduction of medication. The elevated prevalence of MRPs observed among individuals taking omeprazole underscores the necessity for intensified pharmaceutical care (PC). Active interventions by pharmacists—encompassing deprescribing initiatives, dose adjustments, and direct communication with prescribers—have the potential to minimize adverse drug events and foster more secure patterns of omeprazole use.
